fbpx
Sign up now!
Don't show this again
Download the report!Continue to Site >
or wait 7 secs

Thank you for confirming your subscription!

(And remember, if ever you want to change your email preferences or unsubscribe, just click on the links at the bottom of any email.)

We’re glad you’re enjoying Pig Health Today.
Access is free but you’ll need to register to view more content.
Already registered? Sign In
Tap to download the app
X
Share
X

REPORTS

Collect articles and features into your own report to read later, print or share with others

Create a New Report

Favorites

Read Later

Create a new report

Report title (required) Brief description (optional)
CREATE
X
NEXT
PORK POULTRY
follow us


You must be logged in to edit your profile.

Favorites Read Later My Reports PHT Special Reports
Pig Health Today is equipped with some amazing (and free) tools for organizing and sharing content, as well as creating your own magazines and special reports. To access them, please register today.
Sponsored by Zoetis

Pig Health Today | Sponsored by Zoetis

.

PCV2 vaccines remain effective despite growing genetic diversity

The emergence of new genetic variants of porcine circovirus 2 (PCV2) has raised concerns about the ability of commercial PCV2 vaccines to protect pigs from infection. However, a recent publication in Pathogens confirms that current vaccines continue to be effective, suggesting the existence of a single PCV2 serotype despite the significant and growing number of genotypes.1

PCV2 vaccines have “remarkably decreased the impact of PCV disease and the detrimental effects of subclinical infection” since they first became available, noted authors Giovanni Franzo, of Italy’s University of Padua, and Joaquim Segalés, of Spain’s Universitat Autónoma de Barcelona and Institute of Agrifood Research and Technology. However, they added, PCV2 is characterized by a high mutation rate that has led to the emergence of many variants over time.

The impact of PCV2 genetic and phenotypic diversity on vaccine efficacy is therefore a topic of intense debate, particularly after the emergence of PCV2d. The vast majority of currently available vaccines are based on PCV2a or its capsid protein, they noted, and the discovery of different neutralizing epitopes among genotypes could justify the concern regarding differential cross-protection and the presence of vaccine-escape variants.

Multiple genotypes, one serotype

To shed light on this debate, Franzo and Segalés conducted a comprehensive review of available knowledge on PCV2 genetic heterogeneity, immunity and vaccine efficacy, organizing and harmonizing the available data from different sources. Although genotype variability is likely to increase in the future, the researchers found that cross-immunity is present among major genotypes (PCV2a, PCV2b and PCV2d).

“This ensures, thus far, the vaccine-induced protection by those products based on PCV2a. Therefore, to date, we consider that the different genotypes of PCV2 still represent one single viral serotype,” they wrote.

“In other words, PCV2 genotypes conform to a unique immunological variant with common antigenic properties covered by existing commercial vaccines.”

In all instances, PCV2 vaccines appeared to effectively reduce clinical signs, viremia, viral shedding and lesions while inducing adequate humoral and cellular immune responses, they noted.

“No obvious evidence of a clinically significant differential cross-protection among PCV2 strains could be proven, and all commercial vaccines seem effective in preventing the most severe outcomes of PCV2 infection.”

Additional valency may improve protection, limit viral evolution

Although proper herd management is critical, they wrote, the improvement and update of PCV2 vaccines could likely have further benefits for animal health and performance.

“The inclusion of additional valency in vaccines has been suggested by several authors and recently implemented in some commercial vaccines, where…recombinant chimeric PCV1 expressing the porcine circovirus type PCV2a and PCV2b ORF2 genes was developed,” the authors stated.

“The presence of PCV2b, in addition to the direct improved protection against homologous challenge, could be beneficial against other genotypes, both because of its closer genetic distance than PCV2a and because of a likely increase in protection breadth due to the presence of a combination of different epitopes.”

The beneficial effect of different epitope combinations rather than simple genetic resemblance  is scientifically supported, the authors added.

“Limiting viral evolution and preventing further vaccine-escaping variant emergence is another fundamental task for PCV2 vaccinology monitoring,” they wrote. “Also in this case, the use of a combination of different genotypes is likely to be helpful. A combination would create a more heterogeneous immune response from which the escape of specific, single mutations would be less likely.”

Comparable evidence emerges for other pathogens of veterinary interest, for which the combination of vaccines based on different genotypes has been traditionally considered a highly effective way to protect animals from new emerging variants of viral infectious diseases.

Additional studies should be performed under experimental as well as field conditions, the researchers recommended. They noted particular care should be given to the analysis of viral evolution at the individual level.

 

To read the full study, click here.

 

1 Franzo G, Segalés S. Porcine Circovirus 2 Genotypes, Immunity and Vaccines: Multiple Genotypes but One Single Serotype. Pathogens. 2020;9:1049. doi:10.3390/pathogens9121049

 

 

Share It
The emergence of new genetic variants of PCV2 has raised concerns about the ability of commercial vaccines to protect pigs from infection. However, a recent publication in Pathogens confirms that current vaccines continue to be effective.

Click an icon to share this information with your industry contacts.



Posted on June 22, 2021

tags: , , ,
RELATED NEWS



You must be logged in to edit your profile.

Share It
A recent study shows it’s feasible to obtain data on antimicrobial use while keeping information confidential, said Peter Davies, PhD, principal investigator and professor in the College of Veterinary Medicine at the University of Minnesota.

Click an icon to share this information with your industry contacts.
Google Translate is provided on this website as a reference tool. However, Poultry Health Today and its sponsor and affiliates do not guarantee in any way the accuracy of the translated content and are not responsible for any event resulting from the use of the translation provided by Google. By choosing a language other than English from the Google Translate menu, the user agrees to withhold all liability and/or damage that may occur to the user by depending on or using the translation by Google.